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INTRODUCTION
Zolmitriptan belongs to the class of
anti-migraine medications that targets the
5-hydroxytryptamine (5-HT) serotonin
receptor (triptans). When this class of
drugs was conceived, the 5-HT1 receptor
was thought to abort migraines by causing
vasoconstriction solely in the cerebral vas-
culature. However, vasoconstrictive
effects on the coronary circulation have
been widely documented in vivo and in
vitro, due to either the presence of 5-HT1
receptors, other 5-HT1-type receptors in
coronary arteries, or ranging degrees of
receptor reactivity of these drugs [1-3].
Although chest symptoms, including
chest pressure, tightness, and pain, have been
described in up to 15 percent of patients tak-
ingthesedrugs,cardiovascularadverseevents
such as myocardial infarction (MI) have
rarely been reported in the literature [3-10].
The mechanism for these events is thought to
be related to vasoconstriction superimposed
on a pre-existing coronary lesion.
REPORT OF A CASE
This 68-year-old woman had a history
of migraines with visual aura since she
was 48 years of age. She averaged one to
two attacks every week and had been tak-
ing zolmitriptan for six years. She routine-
ly took 5 mg orally for every episode and
had an adequate response, rarely requiring
a second dose. There was no history of
hypertension, diabetes, hyperlipidemia,
ischemic heart disease, cerebrovascular
disease, smoking, or family history of pre-
mature atherosclerotic disease. She had
never experienced any chest pain prior to
this episode.
On the day of admission, the patient
experienced a typical migraine attack around
11 a.m. and took 5 mg of zolmitriptan. Five
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We report the case of a patient with mild non-obstructive coronary artery disease who sus-
tained an inferior wall myocardial infarction shortly after taking zolmitriptan as abortive ther-
apy for migraine headaches. A Medline search was performed to review all reported cases
of myocardial infarction related to migraine therapy with zolmitriptan and related medica-
tions. Zolmitriptan may cause myocardial infarction (MI) even in the absence of significant
coronary artery disease.hourslatershehadsuddenonsetofchestpain
while lying in bed. She described the pain as
pressure which was localized to the retroster-
nal area and radiated to the left breast, neck,
and left arm. The pain was severe in intensi-
ty (8/10) initially and decreased gradually
over the next three hours to a moderate pain
(4/10).At that time, she repeated the dose of
zolmitriptan for cephalgia, while still having
chest pain. Soon thereafter, she presented to
the emergency department, where she had
normal vital signs, a normal electrocardio-
gram, and normal cardiac enzymes. Another
set of enzymes was drawn four hours later,
revealing a troponin I of 2.36 ng/ml. The
patient was chest-pain free by that time and
wastakentothecatheterizationlaboratory10
hours later.
Angiography revealed mild two-vessel
coronary artery disease with several
stenoses, none of which was greater than 30
to40percent.Leftventriculographydemon-
strated severe diaphragmatic hypokinesis,
and the troponin I level later peaked at 7.99
ng/mL (Figure 1).
COMMENT
Zolmitriptan, a 5HT1 agonist, belongs
to a class of anti-migraine drugs that are
known to cause vasoconstriction, precipi-
tating chest pain in up to 15 percent of
patients, but rarely causing serious cardio-
vascular events. Several reports of MI in
patients receiving sumatriptan, a close rel-
ative to zolmitriptan, appear in the litera-
ture. However, a patient with confirmed
MI by elevated cardiac enzymes and a
wall-motion abnormality demonstrated by
left ventriculography with non-obstructive
coronary disease on coronary angiogram
had not been reported until a recent case
report by Mikhail et al. involving
zolmitriptan [10]. Our case represents the
second such documented MI attributable
to zolmitriptan in a similar patient without
known coronary artery disease.
As was the case in Mikhail et al.'s
case of MI due to zolmitriptan, we demon-
strated non-obstructive coronary artery
disease with coronary angiography per-
formed the morning after symptom onset.
Both troponin I elevation and a hypokinet-
ic diaphragmatic segment on left ventricu-
lography confirmed the presence of MI
(See Figure 1). Given the known vasocon-
strictive effects of the triptans and the tem-
poral relationship between our patient's
self-administration of zolmitriptan and her
clinical presentation, this case implies a
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Figure 1. Severe diaphragmatic hypokinesis demonstrated by left ventriculography.causal relationship between zolmitriptan
and MI even in the absence of significant
coronary artery stenoses.
In two of the earlier reported cases of
triptan-induced MI, there was no enzymat-
ic evidence of myocardial necrosis [4, 5].
Coronary angiography revealed normal
coronary arteries and minor luminal irreg-
ularities, respectively. In a third case, an
inferior MI was diagnosed shortly after
sumatriptan use, but coronary angiography
was not performed [6]. In a fourth case,
the patient had severe underlying coronary
artery disease and a history of cocaine
abuse [7].Another case described a patient
with moderate atherosclerotic disease and
an anterior wall MI after sumatriptan and
methylsergide use [8].
In a sixth case, the patient presented
with polymorphic ventricular tachycardia
and an inferior ST-elevation MI with tro-
ponin I elevation to 31.9 ng/ml.
Angiography revealed a totally occluded
non-dominant right coronary, and the
patient's history of diabetes mellitus and
tobacco abuse make underlying coronary
artery disease probable [11].
While almost all previously reported
MIs thought secondary to triptan use have
occurred after administration of sumatrip-
tan, recent reports involving tegaserod [9]
and zolmitriptan [10] point to a possible
class effect for these anti-migraine med-
ications. This class effect is not unexpect-
ed, as Zolmitriptan has a similar mecha-
nism of action to other triptans [12].
Vijayan et al. reported a case of ischemic
spinal cord infarction thought secondary to
zolmitriptan [13]; Carnero et al. described
angina related to zolmitriptan use [14]; and
ours is now the second case of zolmitrip-
tan-induced MI in the literature [10].
Our case highlights the significant
challenge in identifying patients at risk for
adverse cardiovascular events with this
class of drugs. Evans et al. suggest a strat-
egy for assessing this risk [15], including
ascertaining cardiac risk factors, screening
electrocardiograms, and non-invasive
ischemia evaluations with stress testing.
However, non-invasive screening tests,
such as nuclear or echocardiographic
stress tests or even invasive diagnostic
procedures, may not be sensitive enough
to detect all patients at risk, as these tests
typically only detect more severe coronary
lesions. A potential role for CT or MR
angiography in screening patients may
eventually give physicians a non-invasive
tool for screening prior to prescribing trip-
tans, but the technology and evidence for
such an approach are currently lacking.
As pointed out by Evans et al. [14],
physicians should attempt to use other
abortive therapies for migraines in patients
with any cardiovascular risk factors. In
those patients for whom no other effective
options exist for migraine therapy, specif-
ic counseling regarding symptoms of
myocardial ischemia should be given by
physicians prescribing these medications.
Our patient took the maximal allowable
dose in a 24-hour period, two 5 mg tablets,
the second of which was taken in the
throes of her cardiac event. More effective
education of our patient concerning the
potential cardiac effects of zolmitriptan
may have dissuaded her from taking the
second pill, which likely exacerbated the
situation. Finally, our patient had frequent
headaches and took zolmitriptan one to
two times per week. The safety of
zolmitriptan in patients with frequent
headaches requiring abortive therapy three
or more times a week is uncertain.
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